(Q34487137)

2 August 2017

title

Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer (English)

1 reference

2 August 2017

1 reference

1 reference

David G McLeod

1

1 reference

2 August 2017

Peter Iversen

2

1 reference

2 August 2017

William A See

3

1 reference

2 August 2017

Thomas Morris

4

1 reference

2 August 2017

Jon Armstrong

5

1 reference

2 August 2017

Manfred P Wirth

6

1 reference

2 August 2017

Casodex Early Prostate Cancer Trialists' Group

7

1 reference

2 August 2017

publication date

1 February 2006

1 reference

2 August 2017

1 reference

2 August 2017

volume

97

1 reference

2 August 2017

issue

2

1 reference

2 August 2017

page(s)

247-254

1 reference

Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31.

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.06051.X

Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.06051.X

Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.06051.X

Treatment options for early prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.06051.X

Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.06051.X

Quality of life compared during pharmacological treatments and clinical monitoring for non-localized prostate cancer: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.06051.X

Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.06051.X

Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.06051.X

Patients' preferences for the management of non-metastatic prostate cancer: discrete choice experiment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.06051.X

Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.06051.X

6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.06051.X

Prospective randomized trial comparing flutamide as adjuvant treatment versus observation after radical prostatectomy for locally advanced, lymph node-negative prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.06051.X

Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.06051.X

Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.06051.X

Prophylactic breast irradiation with a single dose of electron beam radiotherapy (10 Gy) significantly reduces the incidence of bicalutamide-induced gynecomastia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.06051.X

Prevention and management of bicalutamide-induced gynecomastia and breast pain: randomized endocrinologic and clinical studies with tamoxifen and anastrozole

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.06051.X

10.1111/J.1464-410X.2005.06051.X

21 January 2018

Identifiers

DOI

1 reference

2 August 2017

1 reference